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LETTERS TO THE EDITOR
CLADRIBINE IN MYASTHENIA GRAVIS:
A CASE URGING FOR PRUDENCE
We read with interest the recent report by Deftereos 1 sug-
gesting patients presenting with hematologic disorders or
multiple sclerosis (MS) and co-morbid myasthenia gravis
(MG) could be candidates for cladribine treatment, due to
cladribine’s B and T cell depleting mechanism of action.
We present a patient with MS associated with mild ocular
MG who developed generalized MG necessitating intensive
care unit (ICU) admission and ventilation 2 months after
a ﬁrst treatment course with cladribine.
Our index patient is a 55-year-old male. He was diagnosed
with MS in 2011 after 2 relapses and compatible ﬁndings on
brain and spinal cord magnetic resonance imaging (MRI)
and cerebrospinal ﬂuid. Initial treatment with interferon
beta-1a was stopped seven years later due to toxic hepatitis
and teriﬂunomide initiated after normalization of his liver
tests. Due to a relapse with paraparesis, ascending paresthe-
sias and a new gadolinium enhancing lesion at the T5 level
on spinal MRI he was switched to treatment with cladribine.
At the time of this relapse he also noted fatigable ptosis with-
out diplopia. The remainder of his neurological examina-
tion was normal. Single ﬁber EMG of the orbicularis oculi
muscle and testing for acetylcholine receptor antibodies
(anti-AChR-Ab) were negative. No speciﬁc treatment for
myasthenia gravis was initiated. He received a ﬁrst course of
1.75 mg/kg cladribine and presented 3.5 months later with
ﬂuctuating diplopia rapidly evolving into dysarthria, dyspha-
gia, Medical Research Council (MRC) grade 3 weakness
throughout and respiratory insufﬁciency. He was transferred
to the intensive care unit and underwent tracheal intubation.
After plasma-exchange (one exchange every other day over
10 days), methylprednisolone (48 mg) and pyridostigmine
(60 mg four times a day) he rapidly recovered. Hematologi-
cal studies showed a lymphopenia at 540 lymphocytes/μL
(normal range 1000-3000), low B cells at 73/μL (normal
range 100-500), and low T cells (388/μL, lower limit of
normal 500). MUSK antibodies were negative. Anti-AChR-Ab
were repeated, and were now positive at 18 × 10-10 Mol
(reference range 0-5 × 10-10 Mol), chest CT did not reveal
thymic abnormalities, and brain MRI did not reveal new MS
lesions. He developed a thoracic zoster infection and acute
septicemia of urinary origin for which he was treated with
acyclovir and antibiotics. He was discharged 3 weeks after
the onset of this exacerbation on pyridostigmine 60 mg
4 times a day and methylprednisolone 32 mg daily.
A potential role for cladribine treatment in MG was
recently suggested in this journal1 in response to the article
of Yi et al.2 delineating the role of B cells in MG. However,
B cell depletion by cladribine3 is less profound with different
kinetics compared to rituximab which, in usual doses, leads
to complete suppression of B cell counts. A potential prob-
lem with the use of cladribine in MG is the often-long-term
lymphopenia induced by this drug4, making rescue therapy
with other immunosuppressive drugs difﬁcult. We recom-
mend caution in treating MG patients with cladribine.
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